<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Valanti, E.</style></author><author><style face="normal" font="default" size="100%">Tsompanidis, A.</style></author><author><style face="normal" font="default" size="100%">Sanoudou, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacogenomics in the development and characterization of atheroprotective drugs</style></title><secondary-title><style face="normal" font="default" size="100%">Methods Mol BiolMethods Mol BiolMethods Mol Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Methods in molecular biology</style></alt-title><short-title><style face="normal" font="default" size="100%">Methods in molecular biologyMethods in molecular biology</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Drug Discovery</style></keyword><keyword><style  face="normal" font="default" size="100%">*Pharmacogenetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Atherosclerosis/*drug therapy/epidemiology/*genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Fibric Acids/therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2014</style></year></dates><volume><style face="normal" font="default" size="100%">1175</style></volume><pages><style face="normal" font="default" size="100%">259-300</style></pages><isbn><style face="normal" font="default" size="100%">1940-6029 (Electronic)1064-3745 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Atherosclerosis is the main cause of cardiovascular disease (CVD) and can lead to stroke, myocardial infarction, and death. The clinically available atheroprotective drugs aim mainly at reducing the levels of circulating low-density lipoprotein (LDL), increasing high-density lipoprotein (HDL), and attenuating inflammation. However, the cardiovascular risk remains high, along with morbidity, mortality, and incidence of adverse drug events. Pharmacogenomics is increasingly contributing towards the characterization of existing atheroprotective drugs, the evaluation of novel ones, and the identification of promising, unexplored therapeutic targets, at the global molecular pathway level. This chapter presents highlights of pharmacogenomics investigations and discoveries that have contributed towards the elucidation of pharmacological atheroprotection, while opening the way to new therapeutic approaches.</style></abstract><accession-num><style face="normal" font="default" size="100%">25150873</style></accession-num><notes><style face="normal" font="default" size="100%">Valanti, EfiTsompanidis, AlexandrosSanoudou, DespinaengResearch Support, Non-U.S. Gov'tReviewClifton, N.J.2014/08/26 06:00Methods Mol Biol. 2014;1175:259-300. doi: 10.1007/978-1-4939-0956-8_11.</style></notes><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, Athens, 115 27, Greece.</style></auth-address></record></records></xml>